Hedysarum polysaccharide alleviates oxidative stress to protect against diabetic peripheral neuropathy via modulation of the keap1/Nrf2 signaling pathway

Li, He; Huan, Peng-fei; Xu, Jing; Chen, Yanxu; Zhang, Lei; Wang, Jun; Wang, Li; Jin, Zhensheng

doi:10.1016/j.jchemneu.2022.102182

Cited by 8 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During cellular stress, ROS oxidizes Keap1, leading to the release and nuclear translocation of Nrf2 (He et al. 2022 ). Nrf2 regulates downstream antioxidant response elements (AREs), including nucleotide adenosine diphosphate hydrolase (NADH), haem oxygenase-1 (HO-1), quinone oxidoreductase-1 (NQO1), and glutamylcysteine ligase (GCLC) (Leng et al.…”

Section: Methodsmentioning

confidence: 99%

Advances of traditional Chinese medicine preclinical mechanisms and clinical studies on diabetic peripheral neuropathy

Zhang,

Wu,

Yao

et al. 2024

Pharmaceutical Biology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Advances of traditional Chinese medicine preclinical mechanisms and clinical studies on diabetic peripheral neuropathy

Zhang,

Wu,

Yao

et al. 2024

Pharmaceutical Biology

View full text Add to dashboard Cite

“…The KEAP1 is a substrate‐recognizing subunit of cullin RING ligase (CRL), responsible for ubiquitylation and subsequent degradation of antioxidant transcription factor nuclear factor erythroid 2‐related factor 2 (Nrf2) 26,386–389 . Structurally, KEAP1 mainly consists of an N‐terminal bric‐a‐brac of tramtrack, a broad complex (BTB) domain for cullin 3 binding, and a C‐terminal Kelch domain for substrate recruitment 390–393 . Recently, a number of small molecules have been shown to modulate the KEAP1/NRF2 axis (Figure 6).…”

Section: Keap1 Ligands and Their Utilizations In Protacsmentioning

confidence: 99%

“… 26 , 386 , 387 , 388 , 389 Structurally, KEAP1 mainly consists of an N‐terminal bric‐a‐brac of tramtrack, a broad complex (BTB) domain for cullin 3 binding, and a C‐terminal Kelch domain for substrate recruitment. 390 , 391 , 392 , 393 Recently, a number of small molecules have been shown to modulate the KEAP1/NRF2 axis (Figure 6 ). 284 , 394 , 395 , 396 , 397 , 398 The BTB domain inhibitors, including natural products KEAP1‐1 (a semi‐synthetic oleanolic acid derivative bardoxolone) and KEAP1‐2 (piperlongumine), were discovered as a promising NRF2 modulators utilized in TPD applications by covalently interacting with cysteine residues of KEAP1.…”

Section: Keap1 Ligands and Their Utilizations In Protacsmentioning

confidence: 99%

PROTACs: A novel strategy for cancer drug discovery and development

Han

Sun

2023

MedComm

View full text Add to dashboard Cite

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists of three components: a small molecule that binds to a target protein, an E3 ligase ligand (consisting of an E3 ligase and its small molecule recruiter), and a chemical linker that hooks first two components together. In the past 20 years, we have witnessed advancement of multiple PRO-TAC degraders into the clinical trials for anticancer therapies. However, one of the major challenges of PROTAC technology is that only very limited number of E3 ligase recruiters are currently available as E3 ligand for targeted protein degradation (TPD), although human genome encodes more than 600 E3 ligases. Thus, there is an urgent need to identify additional effective E3 ligase recruiters for TPD applications. In this review, we summarized the existing RING-type E3 ubiquitin ligase and their small molecule recruiters that act as effective E3 ligands of PRO-TAC degraders and their application in anticancer drug discovery. We believe that this review could serve as a reference in future development of efficient E3 ligands of PROTAC technology for cancer drug discovery and development.

show abstract

“…Besides, HPS significantly suppressed MDA concentration and enhanced the concentration of antioxidant enzymes in HG-induced Schwann cells. Moreover, HPS stimulated Nrf2 signalling, whereas decreased Keap1 expression in SCs ( He et al, 2022 ). Therefore, HPS has been demonstrated to have antioxidant activity both in vivo and in vitro and can be considered as a potential diabetes treatment.…”

Section: Application Of Natural Polysaccharides In Treating Diabetes ...mentioning

confidence: 99%

Polysaccharides from natural resource: ameliorate type 2 diabetes mellitus via regulation of oxidative stress network

He,

Li,

Niu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia that can occur in children, adults, elderly people, and pregnant women. Oxidative stress is a significant adverse factor in the pathogenesis of DM, especially type 2 diabetes mellitus (T2DM), and metabolic syndrome. Natural polysaccharides are macromolecular compounds widely distributed in nature. Some polysaccharides derived from edible plants and microorganisms were reported as early as 10 years ago. However, the structural characterization of polysaccharides and their therapeutic mechanisms in diabetes are relatively shallow, limiting the application of polysaccharides. With further research, more natural polysaccharides have been reported to have antioxidant activity and therapeutic effects in diabetes, including plant polysaccharides, microbial polysaccharides, and polysaccharides from marine organisms and animals. Therefore, this paper summarizes the natural polysaccharides that have therapeutic potential for diabetes in the past 5 years, elucidating their pharmacological mechanisms and identified primary structures. It is expected to provide some reference for the application of polysaccharides, and provide a valuable resource for the development of new diabetic drugs.

show abstract

Hedysarum polysaccharide alleviates oxidative stress to protect against diabetic peripheral neuropathy via modulation of the keap1/Nrf2 signaling pathway

Cited by 8 publications

References 27 publications

Advances of traditional Chinese medicine preclinical mechanisms and clinical studies on diabetic peripheral neuropathy

Advances of traditional Chinese medicine preclinical mechanisms and clinical studies on diabetic peripheral neuropathy

PROTACs: A novel strategy for cancer drug discovery and development

Polysaccharides from natural resource: ameliorate type 2 diabetes mellitus via regulation of oxidative stress network

Contact Info

Product

Resources

About